Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is safe and well-tolerated in healthy elderly volunteers, showing a favourable pharmacokinetic profile and high brain penetration. These findings support the advancement of SUL-238 into further clinical development for Alzheimer's and other neurodegenerative diseases.
Read MoreThis acquisition expands neurocare’s clinic network to 11 locations in the Netherlands and marks a key step into care focused on pregnancy, early parenthood, and family wellbeing.
Read More
"This Wasn't DEA Marijuana Regulation - It Was a DEA Illegal Ambush." ALL EYES ON TERRY COLE!
MMJ BioPharma Cultivation CEO Duane Boise is calling out the DEA's desperate attempt to defend a marijuana Administrative Law Judge decision that never got a hearing, blocked marijuana scientific evidence, and defied Supreme Court precedent.
Read More"They're defending a hearing that never actually happened," said Duane Boise.
"We followed every rule. They followed none."
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
Read More
Physicians Assess AI Tools Against 12 Frontline KPIs; 8 Solutions Surpass Expectations in Diagnostic Alignment, Workflow Support, and Communication Quality
Read MoreThis unique cellular activity may help restore energy balance and improve essential cell functions such as protein synthesis and membrane stability in diseases like Parkinson's ALS Alzheimer's and Progeria where mitochondrial failure and oxidative stress drive progression
Read More
As the DEA's unconstitutional house of cards collapses, its top obstructionists are fleeing like rats from a sinking ship. Judge John "McLooney" Mulrooney, the DEA's clownish Administrative Law Judge who presided over sham marijuana hearings now deemed unconstitutional, is retiring August 1. Policy chief Matthew Strait has already retired. Thomas Prevoznik, is rumored to be next. And all eyes are now on Aarathi Haig, DEA's lead counsel. Who will be the next to jump ship?
Read More
Startup Introduces AI-Powered Voice-Based Cognitive Screening and Care Planning Platform, Guided by Expert in Aging, Neuropsychology and Implementation Science
Read More
Whether it involves the DEA's much-publicized marijuana rescheduling efforts or MMJ BioPharma's lawful pursuit of a federal registration to conduct FDA-authorized clinical trials, one immovable obstacle remains: the DEA's constitutionally defective administrative adjudication system. Presided over by Chief Administrative Law Judge John J. Mulrooney II, this internal tribunal-often referred to as a "kangaroo court"-violates foundational principles of due process and Article II of the U.S. Constitution.
Read More
N-trans-caffeoyltyramine (NCT) is a natural bioactive compound attracting considerable interest from researchers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity.
Using eXoZymes' AI-driven platform, a new and proprietary approach to biomanufacturing of NCT - with all the scale-up advantages of an exozyme biosolution - has been developed: Progressing from concept to lab scale validation with gram-scale production in only 5 months and at a fraction of normal SynBio R&D cost.
NCTx was created as a spin-out company to commercialize the NCT technology and is now able to provide early access partners, under material transfer agreement with product samples. NCTx and eXoZymes are actively looking to increase the number of partners.
Sublingual nano technology delivers 50mg of caffeine rapidly to the body, bringing its unique benefits to the pre-workout market
Read More
All the news about the DEA administrator and Rescheduling marijuana means absolutely nothing if the quota system remains untouched.
Much attention has been given to breaking Ole Miss's monopoly and who becomes the next DEA Administrator. But the real news isn't about who's appointed-it's what the DEA does with the quota system.
Read More
-- David Cory is an industry veteran, bringing more than 30 years of operational experience, in private and public, emerging-stage biotech and large pharma companies with an established track record of building and leading high performing operating teams and financing in the capital markets with over $1B+ raised and multiple company exits by acquisition
-- CID-103 is a potential best in class, anti-CD38 monoclonal antibody, currently dosing in a multi-center Phase 1/2 study in adults with chronic immune thrombocytopenia (ITP); IND submitted to support future clinical trials in adults with renal allograft antibody-mediated rejection (AMR)
Read MoreIcotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor
Filing based on unprecedented data package that met all primary endpoints across four Phase 3 studies, including head-to-head superiority comparisons versus deucravacitinib and evaluation of difficult to treat skin sites
Submission underscores potential to offer moderate-to-severe plaque psoriasis patients the standout combination of complete skin clearance, favorable safety profile, and simplicity of a once-daily pill
Read More
As thousands suffer without access to FDA-approved cannabis treatments, MMJ BioPharma Cultivation is waging a David vs. Goliath legal war against the DEA's decade-long deception-and incoming Administrator Terrance Cole must decide whether to continue the cover-up or finally put patients over politics.
Read MoreNew data shows Telomir-1 fully reverses STAT1 gene silencing by DNA methylation - a key immune regulator suppressed in cancer - delivering stronger epigenetic effects than Paclitaxel or Rapamycin in aggressive PC3 tumor models.
Read More
Full Interview with MMJ CEO Duane Boise to Air Today @ 9.am ET on Cannabis Coast to Coast News.
Terrance Cole, the nominee for DEA Administrator, must confront this DEA rot head on. The agency's marijuana program is a train wreck. The public deserves answers. And legitimate companies like MMJ BioPharma Cultivation deserve justice.
Boise's growing prominence in advanced urologic care was highlighted recently when Dr. Austen Slade welcomed visiting physicians from Stanford University and the University of Washington to observe and study the HoLEP (Holmium Laser Enucleation of the Prostate) procedure under his guidance.
Read More
